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OBJECTIVE — To evaluate if baseline serum lipids are associated with islet graft survival in
type 1 diabetes islet transplant (ITx) recipients.
RESEARCH DESIGN AND METHODS — Baseline fasting lipid proﬁle was collected
from 44 ITx recipients. Comparisons were performed between subjects below and above the
median values of each lipid fraction. Differences in outcomes were compared by Kaplan-Meier
curves and Cox regression analysis.
RESULTS — Subjects with baseline fasting plasma triglycerides and VLDL cholesterol above
the median had shorter islet graft survival (triglycerides: 39.7  6.1 vs. 61.3  6.6 months, P 
0.029, and VLDL: 41.5  5.7 vs. 62.8  7.3 months, P  0.032). Total, LDL, and HDL
cholesterol did not inﬂuence islet function. Triglycerides (odds ratio 2.97 [95% CI 1.03–8.52],
P  0.044) maintained its association with graft failure after adjustments for confounders.
CONCLUSIONS — Higher baseline triglycerides are associated with earlier decline in islet
graft function. Prospective clinical trials should address whether it is directly caused by lipotox-
icity and if strategies focusing on lowering serum lipids may prolong islet graft survival.
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I
ncreased free fatty acids (FFAs) cause
-cell dysfunction and death (1–3).
-Cell lipid accumulation is mediated
by defective intracellular lipid oxidation
associated with leptin resistance (4). This
abnormality can be corrected by insulin
sensitizers or leptin therapy (5,6). In ad-
dition, FFA-induced endoplasmic reticu-
lum stress has been implicated in -cell
apoptosis (7), which could be minimized
by glucagon-like peptide-1 agonists (8).
Islet grafts infused directly into the liver
receive lipid-rich postprandial blood. In-
sulin secreted by islet grafts promote tri-
glyceride deposition in surrounding
hepatocytes, and multifocal steatosis has
beenreportedin20%ofislettransplant
(ITx) recipients (9,10). Moreover, an in-
sulin resistance phenotype and tendency
for higher serum triglycerides, factors as-
sociated with steatosis (11), were predic-
torsofshortergraftsurvival(12).Theaim
of this study was to determine whether
the lipid proﬁle of type 1 diabetic ITx re-
cipients is associated with islet graft
survival.
RESEARCH DESIGN AND
METHODS— A retrospective cohort
studywasconductedin44type1diabetic
subjects (37 ITx alone subjects; 7 islet after
kidney [IAK] subjects), post–allogeneic
ITx between 2000 and 2007 (follow-up
40.9  23.5 months). All patients have
achieved the goal of glucose stability and
avoidance of hypoglycemia, and 28
(64%) achieved insulin independence.
ITx-related procedures were previously
described (13). Immunosuppressive reg-
imen consisted of tacrolimus and siroli-
mus. Three IAK recipients were on
corticosteroid maintenance doses. Four-
teensubjectswereconvertedtomycophe-
nolate mofetil or mychophenolic acid, as
per protocol (n  6) or due to side effects
(n  8). Protocol procedures were ap-
proved by the University of Miami Health
ResearchEthicsBoard,andinformedcon-
sent was obtained.
Clinical variables (demography, an-
thropometry, and family history of type 2
diabetes),insulindosageperkilogram,is-
let autoantibodies, number of infusions
and islet equivalents infused, exenatide
use, and immunosuppressive medication
were recorded. Outcomes were graft dys-
function (positive C-peptide, fasting glu-
cose 140 mg/dl and/or postprandial
glucose 180 mg/dl more than three
times in a 1-week period, and/or A1C
6.5% in two consecutive measure-
ments)andgraftfailure(fastingC-peptide
0.10 ng/ml [two consecutive measure-
ments in absence of hypoglycemia] or
stimulated C-peptide 0.3 ng/ml).
Fasting lipids (total cholesterol, HDL
cholesterol, VLDL cholesterol, and trig-
lycerides) were measured by enzymatic
method, and LDL cholesterol was calcu-
lated (Friedewald equation). Medians of
serumlipidswerecalculated(totalcholes-
terol:177mg/dl,LDL:96mg/dl,HDL:67
mg/dl,VLDL:13mg/dl,andtriglycerides:
65 mg/dl). Fasting glucose (hexokinase),
A1C (high-performace liquid chromatog-
raphy; BioRad, Richmond, CA), and au-
toantibodies (radioimmunoassay) were
obtained. C-peptide was measured by
double antibody radioimmunoassay at
fasting and during a mixed-meal test
(Boost high protein; Novartis/Sandoz,
Nestle Nutrition). Kaplan-Meier curves
(log-rank [Mantel-Cox] test) were used to
comparetimetooutcomes(graftdysfunc-
tion and failure) between subjects with
lipids below and above their median
value. Adjustments for confounders were
performedwithCoxregressionanalysis.P
values of 0.05 (two-tailed) were signif-
icant (SSPS version 16.0).
RESULTS — Age at ﬁrst ITx was 43.0 
8.6 years, and diabetes duration was
30.5  11.7 years. Eighteen (41%) recip-
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jects with baseline fasting plasma
triglyceridesabovethemedianhadearlier
graft dysfunction (6.1  1.5 vs. 17.3 
3.4 months, P  0.001) and failure
(39.7  6.1 vs. 61.3  6.6 months, P 
0.029)(Fig.1A)incomparisonwiththose
with lower values. Similar results were
found for VLDL cholesterol (dysfunction:
6.2  1.6 vs. 16.7  3.2 months, P 
0.001; failure: 41.5  5.7 vs. 62.8  7.3
months,P0.032)(Fig.1B).Total,LDL,
and HDL cholesterol were not determi-
nants of islet function (data not shown).
To clarify if variables associated with
higher triglycerides and/or VLDL choles-
terol were determinants of shorter graft
survival, we compared clinical and labo-
ratory characteristics of subjects below
and above their median values (data not
shown).Patientswithtriglyceridesand/or
VLDL cholesterol above median were
more frequently male and IAK protocol
participants, had positive family history
of type 2 diabetes and overweight, were
on higher doses of insulin per kilogram
pre-ITx, and received a longer period of
sirolimus/tacrolimus combination. These
variables were included in multivariate
analysis with time-to-graft-failure as the
dependant variable. Triglycerides (odds
ratio 2.97 [95% CI 1.03–8.52], P 
0.044) sustained its association with graft
failure, while VLDL cholesterol (3.06
[0.99–9.45],P0.052)attainedborder-
linesigniﬁcance.Othervariableswerean-
alyzed on separate multivariate models
based on their biological relevance (HLA
mismatches, cold ischemia duration, age,
diabetes duration, BMI, autoantibodies,
and immunosuppressant’s serum trough
levels) without modifying the results.
CONCLUSIONS — InITxrecipients,
higher baseline triglycerides predict ear-
lier graft dysfunction and failure. VLDL
cholesterol produced similar outcomes,
probably by the same mechanisms, since
VLDL cholesterol is mainly composed by
triglycerides.
Lipotoxicity has been pointed as one
of the mechanisms responsible for -cell
dysfunction and death in type 2 diabetes
(1). Concerns about similar effects in ITx
have been raised by posttransplant image
studies showing steatosis (9,10). How-
ever, the signiﬁcance of steatosis in hu-
mans is not clear, being described either
as a marker of good function (9) or dys-
function (10).
Recently,lipidtoxicityhasbeenstud-
ied in an animal model of ITx (14), and
liver triglyceride accumulation was asso-
ciated with poorer islet graft function and
histological appearance (reduced -cell
mass and increased islet ﬁbrosis) (14).
Notably, these abnormalities were cor-
rected by therapies targeting lipid supply
(restrictive diet) or deposition (leptin
gene therapy) (14).
Besides direct toxic effects, another
interesting hypothesis connecting higher
triglyceridesandisletgraftsurvivalcanbe
formulated. Lipoprotein apo-C3 pro-
vokes human -cell apoptosis (15). This
lipoprotein is a component of triglycer-
ide-rich VLDL cholesterol molecules,
raising the possibility of an extra mecha-
nism of -cell damage.
To the best of our knowledge, this is
the ﬁrst report of serum lipid association
with islet graft survival in humans. This
ﬁndingaddstotheunderstandingofmul-
tiple and complex mechanisms of -cell
survival and calls attention to potential
newtherapiestargetingserumlipids,pre-
venting lipotoxicity and possibly leading
to longer islet survival.
The study limitations are retrospec-
tive analysis and small sample size. We
are aware that our results are not deﬁni-
tiveandshouldbeconﬁrmedinlargerco-
horts with more detailed laboratorial
analysis,includingmeasurementofFFAs,
and quantiﬁcation of liver lipid deposi-
tion by spectroscopy. Our aim was to
proveaconceptandbringthisideatodis-
cussion. Higher baseline triglycerides are
Figure1—Isletgraftfailureaccordingtoserumlipidsbelow(blackline)andabove(grayline)the
median values for triglycerides (A) and VLDL cholesterol (B). Comparisons were done with
Kaplan-Meier curves and log-rank (Mantel-Cox) test.
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function. Prospective trials should ad-
dress whether it is directly caused by li-
potoxicity and if strategies reducing
serum lipids may prolong islet graft
survival.
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